Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data

Autor: Jun Chen, Xiongfei Li, Song Xu, Yanye Wang, Ming Dong, Dian Ren, Gang Chen, Fan Ren, Zuoqing Song
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
Mutation rate
Candidate gene
Lung Neoplasms
DNA Mutational Analysis
Disease
surgery
0302 clinical medicine
Gene Frequency
Carcinoma
Non-Small-Cell Lung
Medicine
database
Original Research
Cancer Biology
Middle Aged
Prognosis
early stage
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
030220 oncology & carcinogenesis
Adenocarcinoma
Female
medicine.medical_specialty
lcsh:RC254-282
03 medical and health sciences
Internal medicine
TP63
Biomarkers
Tumor
genomics
Adjuvant therapy
Humans
Radiology
Nuclear Medicine and imaging
Lung cancer
Alleles
Aged
Neoplasm Staging
business.industry
Proportional hazards model
Genetic Variation
medicine.disease
Survival Analysis
respiratory tract diseases
lung cancer
030104 developmental biology
Mutation
Tumor Suppressor Protein p53
business
Zdroj: Cancer Medicine, Vol 9, Iss 20, Pp 7686-7694 (2020)
Cancer Medicine
ISSN: 2045-7634
Popis: Background The prognostic factors for early‐stage nonsmall cell lung cancers (NSCLCs) are not well defined. This study aimed to investigate the effect of highly frequent mutations on the outcomes patients with early‐stage NSCLC, particularly those with surgically resected stage I disease. Methods The Cancer Genome Atlas (TCGA) datasets for Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), and Pan‐Lung Cancer (PLC) were accessed via cBioportal and searched to identify patients with stage I NSCLC. We identified candidate genes with a high (>10%) frequency of mutations and copy‐number alterations and examined their effect on overall survival (OS) and disease‐free survival (DFS). The details of clinicopathologic features were analyzed with the Fisher's exact， Mann‐Whitney U test and Cox regression analysis. Survival was analyzed with Kaplan‐Meier curves, and differences were compared with the log‐rank and chi‐square test. Results We identified 408 patients with stage I NSCLC from the PLC dataset. Of the 41 candidate genes with high‐frequency mutation rates, six genes were significantly associated with OS: TP53, LPP, MAP3K13, FGF12, BCL6, and TP63. Further stratified analysis in PLC, LUAD, and LUSC datasets, we only identified that TP53 was significantly associated with OS in patients with surgically resected stage I lung adenocarcinoma. Conclusions TP53 mutations are potentially markers of poor prognosis for stage I lung adenocarcinoma patients. The mutation status of this gene may contribute to clinical decision‐making with respect to selecting patients who may benefit from adjuvant therapy.
TP53 mutations are potentially markers of poor prognosis for stage I lung adenocarcinoma patients. The mutation status of this gene may contribute to clinical decision‐making with respect to selecting patients who may benefit from adjuvant therapy.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje